{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:08:54Z","timestamp":1793200134799,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10147-025-02769-3","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T14:04:05Z","timestamp":1746194645000},"page":"1060-1068","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Revisiting resectability of biliary tract cancers, in the triplet drug therapy era with immune checkpoint inhibitors"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8828-1067","authenticated-orcid":false,"given":"Shogo","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisaku","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"2769_CR1","volume-title":"General rules for Clinical and pathological studies on cancer of the biliary tract: the","author":"Japanese Society of Hepato-Biliary-Pancreatic Surgery","year":"2021","unstructured":"Japanese Society of Hepato-Biliary-Pancreatic Surgery (2021) General rules for Clinical and pathological studies on cancer of the biliary tract: the, 7th edn. Kanehara, Tokyo","edition":"7"},{"issue":"6","key":"2769_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60(6):1268\u20131289","journal-title":"J Hepatol"},{"key":"2769_CR3","unstructured":"Gan joho service https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/cancer\/index.html"},{"key":"2769_CR4","volume-title":"The general rules for the clinical and pathological study of primary liver cancer: the 6th edition, revised version","author":"Liver cancer study group of Japan","year":"2019","unstructured":"Liver cancer study group of Japan (2019) The general rules for the clinical and pathological study of primary liver cancer: the 6th edition, revised version. Kanehara, Tokyo"},{"key":"2769_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/jhbp.233","volume":"22","author":"M Miyazaki","year":"2015","unstructured":"Miyazaki M, Yoshitomi H, Miyakawa S et al (2015) Clinical practice guidelines for the management of biliary tract cancers2015: the 2nd English edition. J Hepatobiliary Pancreat Sci 22:249\u2013273","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2769_CR6","volume-title":"LCSGJ ICC Guidelines 2021","author":"Liver cancer study group of Japan","year":"2021","unstructured":"Liver cancer study group of Japan (2021) LCSGJ ICC Guidelines 2021. Kanehara, Tokyo"},{"key":"2769_CR7","volume-title":"TNM classification of maliognant tumurs","author":"JD Broerley","year":"2017","unstructured":"Broerley JD, Gospodarowicz MK, Wittekind C (2017) TNM classification of maliognant tumurs, 8th edn. Wiley Blackwell, New York","edition":"8"},{"issue":"7","key":"2769_CR8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","volume":"21","author":"AB Benson III","year":"2023","unstructured":"Benson AB III, D\u2019Angelica AT et al (2023) Guidelines\u00ae insights: biliary tract cancers, Version 2.2023 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 21(7):694\u2013704","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2769_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J et al (2023) Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34(2):127\u2013140","journal-title":"Ann Oncol"},{"issue":"4","key":"2769_CR10","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S1055-3207(02)00036-4","volume":"11","author":"Z Hassoun","year":"2002","unstructured":"Hassoun Z, Gores GJ, Rosen CB (2002) Preliminary experience with liver transplantation in selected patients with unresectable hilar cholangiocarcinoma. Surg Oncol Clin N Am 11(4):909\u2013921","journal-title":"Surg Oncol Clin N Am"},{"issue":"6","key":"2769_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156127","volume":"11","author":"HTJ Mantel","year":"2016","unstructured":"Mantel HTJ, Westerkamp AC, Adam R et al (2016) Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival. PLoS ONE 11(6):e0156127","journal-title":"PLoS ONE"},{"issue":"2","key":"2769_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/SLE.0000000000000510","volume":"28","author":"S Kobayashi","year":"2018","unstructured":"Kobayashi S, Tomokuni A, Takahashi H et al (2018) Laparoscopic hilar lymph node sampling in patients with biliary tract cancers that are rarely associated with nodal metastasis. Surg Laparosc Endosc Percutan Tech 28(2):90\u201395","journal-title":"Surg Laparosc Endosc Percutan Tech"},{"issue":"2","key":"2769_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1089\/lap.2009.0383","volume":"20","author":"PC Giulianotti","year":"2010","unstructured":"Giulianotti PC, Sbrana F, Bianco FM et al (2010) Robot-assisted laparoscopic extended right hepatectomy with biliary reconstruction. J Laparoendosc Adv Surg Tech A 20(2):159\u2013163","journal-title":"J Laparoendosc Adv Surg Tech A"},{"issue":"3","key":"2769_CR14","doi-asserted-by":"publisher","first-page":"e570","DOI":"10.1097\/SLA.0000000000005743","volume":"278","author":"BA Uijterwijk","year":"2023","unstructured":"Uijterwijk BA, Lemmers DHL, Bolm L et al (2023) Long-term outcomes after laparoscopic, robotic, and open pancreatoduodenectomy for distal cholangiocarcinoma: an International Propensity Score-matched Cohort Study. Ann Surg 278(3):e570\u2013e579","journal-title":"Ann Surg"},{"issue":"5","key":"2769_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s005340200076","volume":"9","author":"T Nagakawa","year":"2002","unstructured":"Nagakawa T, Kayahara M, Ikeda S et al (2002) Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg 9(5):569\u2013575","journal-title":"J Hepatobiliary Pancreat Surg"},{"issue":"1","key":"2769_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00534-008-0015-0","volume":"16","author":"S Miyakawa","year":"2009","unstructured":"Miyakawa S, Ishihara S, Horiguchi A et al (2009) Biliary tract cancer treatment: 5584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary. Pancreat Surg 16(1):1\u20137","journal-title":"J Hepatobiliary. Pancreat Surg"},{"issue":"3","key":"2769_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jhbp.314","volume":"23","author":"S Ishihara","year":"2016","unstructured":"Ishihara S, Horiguchi A, Miyakawa S et al (2016) Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci 23(3):149\u2013157","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2769_CR18","unstructured":"NCD (national clinical databse) risk calculator https:\/\/www.ncd.or.jp\/about\/feedback.html"},{"key":"2769_CR19","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/jhbp.1358","volume":"30","author":"F Terasaki","year":"2023","unstructured":"Terasaki F, Hirakawa S, Tachimori H et al (2023) Morbidity after left trisectionectomy for hepato-biliarymalignancies: an analysis of the National Clinical Database of Japan. J Hepatobiliary Pancreat Sci 30:1304\u20131315","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2769_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ags3.12662","volume":"7","author":"Y Kajiwara","year":"2023","unstructured":"Kajiwara Y, Takahashi A, Ueno H et al (2023) Annual report on National Clinical Database 2020 for gastroenterological surgery in Japan. Ann Gastroenterol Surg 7:367\u2013406","journal-title":"Ann Gastroenterol Surg"},{"issue":"14","key":"2769_CR21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273\u20131281","journal-title":"N Engl J Med"},{"issue":"5","key":"2769_CR22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/jso.21971","volume":"104","author":"S Kobayashi","year":"2011","unstructured":"Kobayashi S, Nagano H, Marubashi S et al (2011) Treatment of borderline cases for curative resection of biliary tract cancer. J Surg Oncol 104(5):499\u2013503","journal-title":"J Surg Oncol"},{"issue":"suppl 8","key":"2769_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy282","volume":"29","author":"D Sakai","year":"2018","unstructured":"Sakai D, Kanai M, Kobayashi S et al (2018) Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann Oncol 29(suppl 8):VIII205","journal-title":"Ann Oncol"},{"issue":"1","key":"2769_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka T, Kanai M, Kobayashi S et al (2023) Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci 30(1):102\u2013110","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"suppl 4","key":"2769_CR25","volume":"41","author":"RT Shroff","year":"2023","unstructured":"Shroff RT, Guthrie KA, Scott AJ et al (2023) A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J Clin Oncol 41(suppl 4):LBA490","journal-title":"J Clin Oncol"},{"issue":"4","key":"2769_CR26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00280-014-2543-4","volume":"74","author":"S Kobayashi","year":"2014","unstructured":"Kobayashi S, Nagano H, Sakai D et al (2014) Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study. Cancer Chemother Pharmacol 74(4):699\u2013709","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2769_CR27","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00280-014-2431-y","volume":"73","author":"M Toyoda","year":"2014","unstructured":"Toyoda M, Ajiki T, Fujiwara Y et al (2014) Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004). Cancer Chemother Pharmacol 73(6):1295\u20131301","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2769_CR28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/SLA.0000000000002865","volume":"270","author":"S Kobayashi","year":"2019","unstructured":"Kobayashi S, Nagano H, Tomokuni A et al (2019) A prospective, randomized phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Ann Surg 270(2):230\u2013237","journal-title":"Ann Surg"},{"key":"2769_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejca.2022.01.009","volume":"164","author":"J Edeline","year":"2022","unstructured":"Edeline J, Hirano S, Bertaut A et al (2022) Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies. Eur J Cancer 164:80\u201387","journal-title":"Eur J Cancer"},{"issue":"5","key":"2769_CR30","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20(5):663\u2013673","journal-title":"Lancet Oncol"},{"issue":"10372","key":"2769_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"K Nakachi","year":"2023","unstructured":"Nakachi K, Ikeda M, Konishi M et al (2023) Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 401(10372):195\u2013203","journal-title":"Lancet"},{"issue":"2","key":"2769_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107324","volume":"50","author":"S Kobayashi","year":"2024","unstructured":"Kobayashi S, Nakachi K, Ikeda M et al (2024) Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202. Eur J Surg Oncol 50(2):107324","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"2769_CR33","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, He AR, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1(8):EVIDoa2200015","journal-title":"NEJM Evid"},{"issue":"10391","key":"2769_CR34","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10391):1853\u20131865","journal-title":"Lancet"},{"issue":"3","key":"2769_CR35","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.4049\/jimmunol.1003496","volume":"187","author":"AM Paterson","year":"2011","unstructured":"Paterson AM, Brown KE, Keir ME et al (2011) The programmed death-1 ligand 1:B7\u20131 pathway restrains diabetogenic effector T cells in vivo. J Immunol 187(3):1097\u20131105","journal-title":"J Immunol"},{"issue":"3","key":"2769_CR36","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.4049\/jimmunol.1100056","volume":"187","author":"J Yang","year":"2011","unstructured":"Yang J, Riella LV, Chock S et al (2011) The novel costimulatory programmed death ligand 1\/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol 187(3):1113\u20131119","journal-title":"J Immunol"},{"issue":"26","key":"2769_CR37","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455\u20132465","journal-title":"N Engl J Med"},{"key":"2769_CR38","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-12-1362","volume":"18","author":"DS Chen","year":"2012","unstructured":"Chen DS, Irving BA, Hodi FS (2012) Molecular pathways: next-generation immunotherapy\u2013inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18:6580\u20136587","journal-title":"Clin Cancer Res"},{"key":"2769_CR39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","volume":"131","author":"M Lala","year":"2020","unstructured":"Lala M, Li TR, de Alwis DP et al (2020) A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer 131:68\u201375","journal-title":"Eur J Cancer"},{"issue":"1","key":"2769_CR40","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s12885-024-12225-6","volume":"24","author":"M Niger","year":"2024","unstructured":"Niger M, Nichetti F, Fornaro L et al (2024) A phase II\/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study. BMC Cancer 24(1):436","journal-title":"BMC Cancer"},{"issue":"4 suppl","key":"2769_CR41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS621","volume":"41","author":"S Nara","year":"2023","unstructured":"Nara S, Ioka T, Ogawa G et al (2023) Randomized multicenter phase III trial of neoadjuvant gemcitabine + cisplatin + S-1 (GCS) versus surgery first for resectable biliary tract cancer (JCOG1920: NABICAT). J Clin Oncol 41(4 suppl):TPS621","journal-title":"J Clin Oncol"},{"issue":"2","key":"2769_CR42","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/SLA.0b013e3181be0085","volume":"251","author":"S Hiroaki","year":"2010","unstructured":"Hiroaki S, Kimura F, Yoshidome H et al (2010) Aggressive surgical resection for hilar cholangiocarcinoma of the left-side predominance radicality and safety of left-sided hepatectomy. Ann Surg 251(2):281\u2013286","journal-title":"Ann Surg"},{"issue":"5","key":"2769_CR43","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/jso.21501","volume":"101","author":"S Kobayashi","year":"2010","unstructured":"Kobayashi S, Nagano H, Marubashi S et al (2010) Multidetector computed tomography for preoperative prediction of postsurgical prognosis of patients with extrahepatic biliary cancer. J Surg Oncol 101(5):376\u2013383","journal-title":"J Surg Oncol"},{"issue":"4","key":"2769_CR44","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.ejso.2016.12.008","volume":"43","author":"S Kobayashi","year":"2017","unstructured":"Kobayashi S, Tomokuni A, Gotoh K et al (2017) A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer. Eur J Surg Oncol 43(4):763\u2013771","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"2769_CR45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ijsu.2012.12.006","volume":"11","author":"S Kobayashi","year":"2013","unstructured":"Kobayashi S, Nagano H, Marubashi S et al (2013) Clinicopathological features of long-term survivors for advanced biliary tract cancer and impact of the number of lymph nodes involved. Int J Surg 11(2):145\u2013151","journal-title":"Int J Surg"},{"issue":"3","key":"2769_CR46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jso.21811","volume":"103","author":"S Kobayashi","year":"2011","unstructured":"Kobayashi S, Nagano H, Hoshino H et al (2011) Diagnostic value of FDG-PET for lymph node metastasis and outcome of surgery for biliary cancer. J Surg Oncol 103(3):223\u2013229","journal-title":"J Surg Oncol"},{"issue":"2","key":"2769_CR47","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1245\/s10434-021-10820-6","volume":"29","author":"M Kubo","year":"2022","unstructured":"Kubo M, Kobayashi S, Gotoh K et al (2022) Preoperative FDG-positive lymph nodes predict the postoperative prognosis in resectable biliary tract cancers. Ann Surg Oncol 29(2):935\u2013944","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"2769_CR48","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"EV Cutsem","year":"2016","unstructured":"Cutsem EV, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386\u20131422","journal-title":"Ann Oncol"},{"issue":"1","key":"2769_CR49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","volume":"18","author":"S Isaji","year":"2018","unstructured":"Isaji S, Mizuno S, Windsor JA et al (2018) International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 18(1):2\u201311","journal-title":"Pancreatology"},{"issue":"6","key":"2769_CR50","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/ags3.12713","volume":"7","author":"I Nakamura","year":"2023","unstructured":"Nakamura I, Hatano E, Baba H et al (2023) Impact of conversion surgery after chemotherapy in patients with initially unresectable and recurrent biliary tract cancer. Ann Gastroenterol Surg 7(6):1009\u20131020","journal-title":"Ann Gastroenterol Surg"},{"issue":"7","key":"2769_CR51","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/jhbp.1437","volume":"31","author":"Y Yabushita","year":"2024","unstructured":"Yabushita Y, Park JS, Yoon YS et al (2024) Conversion surgery for initially unresectable locally advanced biliary tract cancer: a multicenter collaborative study conducted in Japan and Korea. J Hepatobiliary Pancreat Sci 31(7):481\u2013491","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2769_CR52","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.pan.2023.06.005","volume":"23","author":"A Oba","year":"2023","unstructured":"Oba A, Chiaro MD, Fujii T et al (2023) Conversion surgery\u201d for locally advanced pancreatic cancer: a position paper by the study group at the joint meeting of the International Association of Pancreatology (IAP) & Japan Pancreas Society (JPS) 2022. Pancreatology 23:712\u2013720","journal-title":"Pancreatology"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02769-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02769-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02769-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T06:02:13Z","timestamp":1748498533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02769-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2769"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02769-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SK has received honoraria for lectures, presentations, speaker\u2019s bureaus, and manuscripts from AstraZeneca, MSD, and Taiho Pharmaceutical. All other authors declare no conflicts of interest. The authors report no proprietary or commercial interest in any product mentioned or the concept discussed in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not require ethical approval because it was a review of published articles and did not involve human or animal subjects directly.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}